Active Ingredient: Brivudine

Indication for Brivudine

Population group: only adults (18 years old or older)

Brivudine is used in adults with no abnormality of their immune system (the body’s defences) for the early treatment of shingles (herpes zoster).

For this indication, competent medicine agencies globally authorize below treatments:

125 mg once a day for 7 days

Route of admnistration


Defined daily dose

125 - 125 mg

Dosage regimen

From 125 To 125 mg once every day for 7 day(s)

Active ingredient


Brivudine is a thymidine analogue with antiviral activity, indicated for the early treatment of acute herpes zoster in adult patients. Brivudine is incorporated into the viral DNA and blocks the action of DNA polymerases, thus inhibiting viral replication.

Read more about Brivudine

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.